dc.contributor.author | Parker, C | |
dc.date.accessioned | 2019-06-24T09:43:54Z | |
dc.date.issued | 2018-01 | |
dc.identifier.citation | ESMO open, 2018, 3 (6), pp. e000451 - ? | |
dc.identifier.issn | 2059-7029 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3275 | |
dc.identifier.eissn | 2059-7029 | |
dc.identifier.doi | 10.1136/esmoopen-2018-000451 | |
dc.format | Electronic-eCollection | |
dc.format.extent | e000451 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Report from the ESMO 2018 presidential symposium-Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE. | |
dc.type | Other | |
rioxxterms.versionofrecord | 10.1136/esmoopen-2018-000451 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-01 | |
rioxxterms.type | Other | |
dc.relation.isPartOf | ESMO open | |
pubs.issue | 6 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 3 | |
pubs.embargo.terms | Not known | |
dc.contributor.icrauthor | Parker, Chris | |